|
HU225496B1
(en)
|
1993-04-07 |
2007-01-29 |
Scios Inc |
Pharmaceutical compositions of prolonged delivery, containing peptides
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
|
ATE493998T1
(de)
|
1996-08-08 |
2011-01-15 |
Amylin Pharmaceuticals Inc |
Pharmazeutische zusammensetzung mit einem exendin-4-peptid
|
|
IL128332A0
(en)
|
1996-08-30 |
2000-01-31 |
Novo Nordisk As |
GLP-1 derivatives
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
DE122007000044I2
(de)
|
1997-01-07 |
2011-05-05 |
Amylin Pharmaceuticals Inc |
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
ES2293688T5
(es)
|
1997-08-08 |
2011-05-04 |
Amylin Pharmaceuticals, Inc. |
Nuevos compuestos análogos de la exendina.
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
ATE383867T1
(de)
|
1997-11-14 |
2008-02-15 |
Amylin Pharmaceuticals Inc |
Neuartige exendin agonisten
|
|
MXPA00004670A
(es)
|
1997-11-14 |
2003-07-14 |
Amylin Pharmaceuticals Inc |
Compuestos agonistas de exendina novedosos.
|
|
EP1044015B1
(en)
|
1998-01-09 |
2008-10-08 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides with insulin
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
JP2003522099A
(ja)
|
1998-02-27 |
2003-07-22 |
ノボ ノルディスク アクティーゼルスカブ |
遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
|
|
NZ506839A
(en)
|
1998-03-09 |
2003-05-30 |
Zealand Pharma As |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
WO1999047160A1
(en)
|
1998-03-13 |
1999-09-23 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
|
MXPA00012286A
(es)
|
1998-06-12 |
2002-10-17 |
Bionebraska Inc |
Peptide-1 similar a glucagon mejora la respuesta celular beta a glucosa en sujetos con tolerancia danada de glucosa.
|
|
DE69941510D1
(de)
|
1998-08-10 |
2009-11-19 |
Us Gov Nat Inst Health |
Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
|
|
JP2002524514A
(ja)
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
DE69928006T2
(de)
|
1998-12-22 |
2006-07-13 |
Eli Lilly And Co., Indianapolis |
Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
|
|
ES2278589T3
(es)
|
1999-01-14 |
2007-08-16 |
Amylin Pharmaceuticals, Inc. |
Excendinas destinadas a la inhibicion de glucagon.
|
|
US6902744B1
(en)
|
1999-01-14 |
2005-06-07 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist formulations and methods of administration thereof
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
CZ20013018A3
(cs)
|
1999-03-17 |
2002-02-13 |
Novo Nordisk A/S |
Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
|
|
CA2372214A1
(en)
|
1999-04-30 |
2000-11-09 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
BR0010750A
(pt)
|
1999-05-17 |
2002-02-26 |
Conjuchem Inc |
Peptìdeos insulinotrópicos de longa duração
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
WO2001051078A1
(en)
|
2000-01-10 |
2001-07-19 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
|
|
CN1487836A
(zh)
|
2000-03-14 |
2004-04-07 |
埃米林药品公司 |
胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
|
|
US20020061838A1
(en)
|
2000-05-17 |
2002-05-23 |
Barton Holmquist |
Peptide pharmaceutical formulations
|
|
CN103356996A
(zh)
|
2000-05-19 |
2013-10-23 |
埃米林药品公司 |
Glp-1用于制备治疗急性冠脉综合征的药物的用途
|
|
US7138546B2
(en)
|
2000-08-18 |
2006-11-21 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
|
NZ519752A
(en)
|
2000-10-20 |
2005-04-29 |
Amylin Pharmaceuticals Inc |
Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
|
|
IL155812A0
(en)
|
2000-12-07 |
2003-12-23 |
Lilly Co Eli |
Glp-1 fusion proteins
|
|
AU3938402A
(en)
|
2000-12-13 |
2002-06-24 |
Lilly Co Eli |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
AU2002308706A1
(en)
|
2001-06-01 |
2002-12-16 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
|
WO2003002136A2
(en)
|
2001-06-28 |
2003-01-09 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
|
WO2003092581A2
(en)
|
2001-07-16 |
2003-11-13 |
Hk Pharmaceuticals, Inc. |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
|
ATE408414T1
(de)
|
2001-07-31 |
2008-10-15 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
|
EP1432430A4
(en)
|
2001-08-28 |
2006-05-10 |
Lilly Co Eli |
PREMIXTURES OF GLP-1 AND BASALINSULIN
|
|
MXPA04003569A
(es)
|
2001-10-19 |
2004-07-23 |
Lilly Co Eli |
Mezclas bifasicas de glp-1 e insulina.
|
|
WO2003059934A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
AU2002364586A1
(en)
|
2001-12-21 |
2003-07-30 |
Delta Biotechnology Limited |
Albumin fusion proteins
|
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
PL209734B1
(pl)
|
2002-02-20 |
2011-10-31 |
Emisphere Tech Inc |
Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
|
|
SI1478394T1
(sl)
|
2002-02-27 |
2008-12-31 |
Immunex Corp |
STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
|
|
AU2003224674A1
(en)
|
2002-03-11 |
2003-09-29 |
Hk Pharmaceuticals, Inc. |
Compounds and methods for analyzing the proteome
|
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
WO2003084563A1
(en)
|
2002-04-04 |
2003-10-16 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
|
CA2480858A1
(en)
|
2002-04-10 |
2003-10-23 |
Eli Lilly And Company |
Treatment of gastroparesis
|
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
|
EP1515749B1
(en)
|
2002-06-14 |
2012-08-15 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
WO2004005342A1
(en)
|
2002-07-04 |
2004-01-15 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
|
EP1536835A1
(en)
|
2002-07-09 |
2005-06-08 |
Sandoz AG |
Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
|
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
WO2004012672A2
(en)
|
2002-08-01 |
2004-02-12 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
ES2339112T3
(es)
|
2002-08-21 |
2010-05-17 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG |
8-(3-amino-piperidin-1-il)-xantinas,su preparacion y su uso como medicamentos.
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
BR0314996A
(pt)
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
DK1583541T3
(da)
|
2002-11-20 |
2011-04-11 |
Neuronova Ab |
Forbindelser og fremgangsmåder til at øge neurogenese
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
EP1610811A4
(en)
|
2002-12-17 |
2008-03-26 |
Amylin Pharmaceuticals Inc |
PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
PL1620118T3
(pl)
|
2003-04-08 |
2014-11-28 |
Yeda Res & Dev |
Leki odwracalnie pegylowane
|
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
|
ATE549028T1
(de)
|
2003-05-15 |
2012-03-15 |
Tufts College |
Stabile analoga von glp-1
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
EP2644206B1
(en)
|
2003-05-23 |
2019-04-03 |
Nektar Therapeutics |
PEG derivatives containing two PEG chains
|
|
EP1631308B1
(en)
|
2003-05-30 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
ES2375056T3
(es)
|
2003-06-03 |
2012-02-24 |
Novo Nordisk A/S |
Composiciones pept�?dicas farmacéuticas estabilizadas.
|
|
KR101308912B1
(ko)
|
2003-06-03 |
2013-09-23 |
노보 노르디스크 에이/에스 |
안정화된 약학적 펩티드 조성물
|
|
EP1633390B1
(en)
|
2003-06-03 |
2012-01-18 |
Novo Nordisk A/S |
Stabilized pharmaceutical glp-1 peptide compositions
|
|
PL1633391T3
(pl)
|
2003-06-03 |
2012-03-30 |
Novo Nordisk As |
Stabilizowane farmaceutycznie kompozycje peptydowe
|
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
|
CA2531988C
(en)
|
2003-08-05 |
2016-06-28 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
BRPI0413644A
(pt)
|
2003-08-21 |
2006-10-17 |
Novo Nordisk As |
métodos para separar as duas formas de um polipeptìdeo tendo uma única racemização de aminoácido, e para separar dois polipeptìdeos, produto de polipeptìdeo, e, composição farmacêutica
|
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
EP1667724A2
(en)
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
ES2373660T3
(es)
|
2003-11-13 |
2012-02-07 |
Novo Nordisk A/S |
Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
WO2005081619A2
(en)
|
2003-11-20 |
2005-09-09 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
DK3300721T4
(da)
|
2003-11-20 |
2025-03-03 |
Novo Nordisk As |
Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
|
|
EP1692168B1
(en)
|
2003-12-03 |
2011-07-20 |
Novo Nordisk A/S |
Single-chain insulin
|
|
WO2005058366A2
(en)
|
2003-12-10 |
2005-06-30 |
Nektar Therapeutics Al, Corporation |
Compositions comprising two different populations of polymer-active agent conjugates
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
WO2007065156A2
(en)
|
2005-12-02 |
2007-06-07 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
|
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
CN1938334A
(zh)
*
|
2004-01-30 |
2007-03-28 |
瓦拉塔药品公司 |
Glp－1激动剂和胃泌素化合物的联合使用
|
|
ATE471340T1
(de)
|
2004-02-11 |
2010-07-15 |
Amylin Pharmaceuticals Inc |
Peptide der amylin familie, verfahren zu deren herstellung und verwendung
|
|
NZ579621A
(en)
|
2004-02-11 |
2011-03-31 |
Amylin Pharmaceuticals Inc |
Hybrid polypeptides with selectable properties
|
|
US8603969B2
(en)
|
2004-02-11 |
2013-12-10 |
Amylin Pharmaceuticals, Llc |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
|
US8617613B2
(en)
|
2004-04-15 |
2013-12-31 |
Alkermes Pharma Ireland Limited |
Polymer-based sustained release device
|
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
|
EP1758575A1
(en)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
|
RU2527893C2
(ru)
|
2004-07-19 |
2014-09-10 |
Биокон Лимитед |
Инсулин-олигомерные конъюгаты, их препараты и применения
|
|
WO2006091231A2
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
KR20070085224A
(ko)
|
2004-08-03 |
2007-08-27 |
바이오렉시스 파마슈티칼 코포레이션 |
Ｇｌｐ-1을 포함하는 트랜스페린 융합 단백질을 사용하는혼합 요법
|
|
US20070204633A1
(en)
|
2004-08-16 |
2007-09-06 |
Whisson Maxwell E |
Apparatus and Method for Cooling of Air
|
|
PL1789434T3
(pl)
|
2004-08-31 |
2014-07-31 |
Novo Nordisk As |
Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
US8143391B2
(en)
|
2004-09-07 |
2012-03-27 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing water-soluble hyaluronic acid modification
|
|
JP2008513384A
(ja)
|
2004-09-17 |
2008-05-01 |
ノボ ノルディスク アクティーゼルスカブ |
インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物
|
|
KR101341359B1
(ko)
|
2004-10-01 |
2013-12-13 |
램스코르 인코포레이티드 |
편리하게 이식가능한 서방형 약물 조성물
|
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
|
CA2582464A1
(en)
|
2004-10-13 |
2006-04-27 |
Sanjay Bhanot |
Antisense modulation of ptp1b expression
|
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
|
WO2006051103A2
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
MX2007005521A
(es)
|
2004-11-12 |
2007-05-18 |
Novo Nordisk As |
Formulaciones estables de peptidos insulinotropicos.
|
|
CN101056650A
(zh)
|
2004-11-12 |
2007-10-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
|
CN101128487B
(zh)
|
2004-12-02 |
2012-10-10 |
杜门蒂斯有限公司 |
靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
|
|
EP2360180A3
(en)
|
2004-12-13 |
2012-02-08 |
Amylin Pharmaceuticals Inc. |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
|
US7851565B2
(en)
|
2004-12-21 |
2010-12-14 |
Nektar Therapeutics |
Stabilized polymeric thiol reagents
|
|
DK1831252T3
(da)
|
2004-12-22 |
2009-10-05 |
Lilly Co Eli |
GLP-1 analog fusionsproteinformuleringer
|
|
CA2599594A1
(en)
|
2004-12-24 |
2006-07-13 |
Amylin Pharmaceuticals, Inc. |
Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
|
CN100540565C
(zh)
|
2005-01-14 |
2009-09-16 |
无锡宏创医药科技有限公司 |
修饰的Exendins及其应用
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
US20080233053A1
(en)
|
2005-02-07 |
2008-09-25 |
Pharmalight Inc. |
Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
WO2007022123A2
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
KR20070115947A
(ko)
|
2005-02-11 |
2007-12-06 |
아밀린 파마슈티칼스, 인크. |
선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
DK1888103T3
(da)
|
2005-04-11 |
2012-04-23 |
Amylin Pharmaceuticals Inc |
Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
|
|
US20090043264A1
(en)
|
2005-04-24 |
2009-02-12 |
Novo Nordisk A/S |
Injection Device
|
|
US8097584B2
(en)
|
2005-05-25 |
2012-01-17 |
Novo Nordisk A/S |
Stabilized formulations of insulin that comprise ethylenediamine
|
|
EP1883652A2
(en)
|
2005-05-26 |
2008-02-06 |
Bristol-Myers Squibb Company |
N-terminally modified glp-1 receptor modulators
|
|
US8097239B2
(en)
|
2005-06-06 |
2012-01-17 |
Camurus Ab |
Controlled-release formulations
|
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
ATE553124T1
(de)
|
2005-06-13 |
2012-04-15 |
Imp Innovations Ltd |
Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
|
|
HUE025208T2
(en)
|
2005-06-16 |
2016-03-29 |
Nektar Therapeutics |
Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
|
|
US20070092482A1
(en)
|
2005-08-04 |
2007-04-26 |
Bossard Mary J |
Conjugates of a G-CSF moiety and a polymer
|
|
CA2658678A1
(en)
|
2005-08-06 |
2007-02-15 |
Gerald J. Prud'homme |
Composition and method for prevention and treatment of type i diabetes
|
|
PL1971362T3
(pl)
|
2005-08-19 |
2015-05-29 |
Amylin Pharmaceuticals Llc |
Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
|
|
CN104324362B
(zh)
|
2005-09-14 |
2018-04-24 |
曼金德公司 |
以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
|
|
EP1928499B1
(en)
|
2005-09-20 |
2011-06-29 |
Novartis AG |
Use of a dpp-iv inhibitor to reduce hypoglycemic events
|
|
WO2007047834A2
(en)
|
2005-10-18 |
2007-04-26 |
Biocon Limited |
Oral peptide conjugates for metabolic diseases
|
|
US7687608B2
(en)
|
2005-10-19 |
2010-03-30 |
Smartcells, Inc. |
Methods for reducing the mitogenicity of lectin compositions
|
|
CA2913805A1
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
WO2007064691A1
(en)
|
2005-12-02 |
2007-06-07 |
Nabil Habib Lab |
Treatment of cancer and other diseases
|
|
US20080318861A1
(en)
|
2005-12-08 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Mucosal Delivery of Stabilized Formulations of Exendin
|
|
EP2364735A3
(en)
|
2005-12-16 |
2012-04-11 |
Nektar Therapeutics |
Branched PEG conjugates of GLP-1
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
WO2007073486A2
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
WO2007084460A2
(en)
|
2006-01-18 |
2007-07-26 |
Qps, Llc |
Pharmaceutical compositions with enhanced stability
|
|
CA2638811A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
MX2008013168A
(es)
|
2006-04-13 |
2008-10-27 |
Sod Conseils Rech Applic |
Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos.
|
|
KR101438839B1
(ko)
|
2006-04-14 |
2014-10-02 |
맨카인드 코포레이션 |
글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
EP2029160A2
(en)
|
2006-05-12 |
2009-03-04 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
|
WO2007139941A2
(en)
|
2006-05-26 |
2007-12-06 |
Amylin Pharmaceuticals, Inc. |
Composition and methods for treatment of congestive heart failure
|
|
US20100022457A1
(en)
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
DK2038423T3
(da)
|
2006-06-21 |
2013-04-02 |
Biocon Ltd |
Fremgangsmåde til fremstilling af biologisk aktive polypeptider med insulinotropisk aktivitet
|
|
WO2008038147A2
(en)
|
2006-07-05 |
2008-04-03 |
Foamix Ltd. |
Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
|
|
CN101511868B
(zh)
|
2006-07-24 |
2013-03-06 |
比奥雷克西斯制药公司 |
毒蜥外泌肽融合蛋白
|
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
|
WO2008016729A1
(en)
|
2006-08-04 |
2008-02-07 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
|
EP2359808B1
(en)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
WO2008021560A2
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable properties
|
|
WO2008023050A1
(en)
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
CN101125207B
(zh)
|
2006-11-14 |
2012-09-05 |
上海华谊生物技术有限公司 |
带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
|
|
WO2008073448A2
(en)
|
2006-12-12 |
2008-06-19 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical formulations and methods for making the same
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
CN101663317A
(zh)
*
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
RU2432361C2
(ru)
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
|
RU2477286C2
(ru)
|
2007-01-05 |
2013-03-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
|
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
|
CA2677932A1
(en)
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
WO2008130066A1
(en)
|
2007-04-20 |
2008-10-30 |
Kang Choon Lee |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
WO2008133908A2
(en)
|
2007-04-23 |
2008-11-06 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
WO2008134425A1
(en)
|
2007-04-27 |
2008-11-06 |
Cedars-Sinai Medical Center |
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
|
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
|
CA2689909C
(en)
|
2007-06-08 |
2016-04-05 |
Ascendis Pharma As |
Long-acting polymeric prodrugs of exendin
|
|
EP2158214B1
(en)
|
2007-06-15 |
2011-08-17 |
Zealand Pharma A/S |
Glucagon analogues
|
|
ATE499088T1
(de)
|
2007-07-10 |
2011-03-15 |
Lilly Co Eli |
Glp-1-fc fusionsprotein-formulierung
|
|
US20110034373A1
(en)
|
2007-08-03 |
2011-02-10 |
Eli Lilly And Company |
Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
DK2193142T3
(da)
|
2007-08-30 |
2015-04-20 |
Curedm Group Holdings Llc |
Præparater og fremgangsmåder til anvendelse af pro-øcellepeptider og analoger dertil
|
|
WO2009030771A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
EP2200626A4
(en)
|
2007-09-07 |
2012-02-15 |
Ipsen Pharma Sas |
ANALOGUE OF EXENDIN-4 AND EXENDIN-3
|
|
JP2011500850A
(ja)
|
2007-10-24 |
2011-01-06 |
マンカインド コーポレイション |
Ｇｌｐ−１による副作用を防止する方法
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
WO2009055742A2
(en)
|
2007-10-24 |
2009-04-30 |
Mannkind Corporation |
Delivery of active agents
|
|
MX2010004298A
(es)
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
|
|
ES2509883T3
(es)
|
2007-10-30 |
2014-10-20 |
Indiana University Research And Technology Corporation |
Antagonistas de glucagón
|
|
BRPI0820535B8
(pt)
|
2007-11-16 |
2021-05-25 |
Novo Nordisk As |
composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
|
|
US8710002B2
(en)
|
2007-11-23 |
2014-04-29 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
JP2011506442A
(ja)
|
2007-12-11 |
2011-03-03 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
インスリン分泌性ペプチド結合体の製剤
|
|
MY152979A
(en)
|
2008-01-09 |
2014-12-15 |
Sanofi Aventis Deutschland |
Novel insulin derivatives having an extremely delayed time-action profile
|
|
EP2249853A4
(en)
|
2008-01-30 |
2012-12-26 |
Univ Indiana Res & Tech Corp |
ESTER BASED PEPTIDE PRODRUGS
|
|
AU2009209565B2
(en)
|
2008-02-01 |
2013-09-19 |
Ascendis Pharma As |
Prodrug comprising a self-cleavable linker
|
|
BRPI0905853B1
(pt)
|
2008-02-06 |
2019-03-26 |
Biocon Limited |
Processo para a produção de proteínas recombinantes, melhorando a incorporação de fosfato.
|
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
|
JP2011516541A
(ja)
|
2008-04-07 |
2011-05-26 |
ナショナル インスティテュート オブ イミュノロジー |
糖尿病および他の慢性疾患の治療に有用な組成物
|
|
RU2517135C2
(ru)
|
2008-05-07 |
2014-05-27 |
Меррион Рисерч Iii Лимитед |
Композиции пептидов и способы их получения
|
|
WO2009143285A2
(en)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholestrol and triglycerides
|
|
JP2011523052A
(ja)
|
2008-05-23 |
2011-08-04 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
Ｇｌｐ−１受容体アゴニスト・バイオアッセイ
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
ES2929343T3
(es)
|
2008-06-13 |
2022-11-28 |
Mannkind Corp |
Inhalador de polvo seco accionado por aspiración para la administración de fármacos
|
|
CN102105159B
(zh)
|
2008-06-17 |
2015-07-08 |
印第安纳大学研究及科技有限公司 |
基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
|
|
AR072160A1
(es)
|
2008-06-17 |
2010-08-11 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
|
US8765669B2
(en)
|
2008-06-17 |
2014-07-01 |
Glytech, Inc. |
Glycosylated GLP-1 peptide
|
|
US8450270B2
(en)
|
2008-06-17 |
2013-05-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
|
|
CN102131516B
(zh)
|
2008-06-27 |
2016-03-16 |
杜克大学 |
包含弹性蛋白样肽的治疗剂
|
|
CA2731236A1
(en)
|
2008-07-21 |
2010-01-28 |
Transpharma Medical Ltd. |
Transdermal system for extended delivery of incretins and incretin mimetic peptides
|
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
RS59913B1
(sr)
|
2008-10-17 |
2020-03-31 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
|
PT2373681T
(pt)
|
2008-12-10 |
2017-04-11 |
Glaxosmithkline Llc |
Composições farmacêuticas de albiglutida
|
|
CN102282167B
(zh)
|
2008-12-15 |
2014-08-13 |
西兰制药公司 |
胰高血糖素类似物
|
|
ES2477880T3
(es)
|
2008-12-15 |
2014-07-18 |
Zealand Pharma A/S |
Análogos del glucagón
|
|
EP2370462B1
(en)
|
2008-12-15 |
2014-07-16 |
Zealand Pharma A/S |
Glucagon analogues
|
|
JP5635531B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
PE20120332A1
(es)
|
2008-12-19 |
2012-04-14 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida
|
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
|
DE102009006602A1
(de)
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
MX2011009251A
(es)
|
2009-03-04 |
2011-11-18 |
Mannkind Corp |
Sistema mejorado de suministro de farmaco en polvo seco.
|
|
JP5608686B2
(ja)
|
2009-03-05 |
2014-10-15 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
後退可能な針を備えた薬物送達デバイス
|
|
WO2010120476A2
(en)
|
2009-04-01 |
2010-10-21 |
Amylin Pharmaceuticals, Inc. |
N-terminus conformationally constrained glp-1 receptor agonist compounds
|
|
US8992886B2
(en)
|
2009-04-06 |
2015-03-31 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
|
JP5727459B2
(ja)
|
2009-04-22 |
2015-06-03 |
アルテオゼン， インクＡｌｔｅｏｇｅｎ， Ｉｎｃ |
体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
|
AU2010251140B2
(en)
|
2009-05-20 |
2015-01-29 |
Sanofi-Aventis Deutschland Gmbh |
A bung for drug containing cartridges in drug delivery devices
|
|
WO2010133676A1
(en)
|
2009-05-20 |
2010-11-25 |
Sanofi-Aventis Deutschland Gmbh |
A system comprising a drug delivery device and a cartridge provided with a bung and a method of identifying the cartridge
|
|
EP2435061A4
(en)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
|
|
JP2012529463A
(ja)
|
2009-06-11 |
2012-11-22 |
ノヴォ ノルディスク アー／エス |
２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
|
|
EP2443146B1
(en)
|
2009-06-16 |
2016-10-05 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
RU2012103240A
(ru)
|
2009-07-02 |
2013-08-10 |
Ангиокем Инк. |
Мультимерные пептидные конъюгаты и их применение
|
|
AU2010272944B2
(en)
|
2009-07-13 |
2015-11-19 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
|
US9138462B2
(en)
|
2009-07-31 |
2015-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Prodrugs comprising an insulin linker conjugate
|
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
CN104147611A
(zh)
|
2009-09-30 |
2014-11-19 |
葛兰素集团有限公司 |
具有延长的半衰期的药物融合体和缀合物
|
|
DK2490708T3
(da)
|
2009-10-22 |
2013-04-15 |
Biodel Inc |
Stabiliserede glucagon-opløsninger
|
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
|
KR20120101037A
(ko)
|
2009-10-30 |
2012-09-12 |
오츠카 가가쿠 가부시키가이샤 |
항원성 ｇｌｐ?１ 아날로그의 당쇄 부가체
|
|
RS53827B1
(sr)
|
2009-11-02 |
2015-06-30 |
Pfizer Inc. |
Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola
|
|
EP2496249B1
(en)
|
2009-11-03 |
2016-03-09 |
Amylin Pharmaceuticals, LLC |
Glp-1 receptor agonist for use in treating obstructive sleep apnea
|
|
PT3345593T
(pt)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
|
|
MY180661A
(en)
|
2009-11-13 |
2020-12-04 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
|
US20130053350A1
(en)
|
2009-12-15 |
2013-02-28 |
Metabolic Solutions Development Company, Llc |
Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
|
|
CA2783262A1
(en)
|
2009-12-15 |
2011-07-14 |
Metabolic Solutions Development Company, Llc |
Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
|
|
US20120322728A1
(en)
|
2009-12-15 |
2012-12-20 |
Metabolic Solutions Development Company, Llc |
Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
|
|
KR20120107493A
(ko)
|
2009-12-15 |
2012-10-02 |
메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 |
대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
|
|
JP6006118B2
(ja)
|
2009-12-16 |
2016-10-12 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アナログ及び誘導体
|
|
WO2011075623A1
(en)
|
2009-12-18 |
2011-06-23 |
Latitude Pharmaceuticals, Inc. |
One - phase gel compos ition compri s ing phos pholi pids
|
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
CN101798588B
(zh)
*
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
|
US20130157953A1
(en)
|
2010-01-20 |
2013-06-20 |
Zealand Pharma A/S |
Treatment of cardiac conditions
|
|
KR20120123443A
(ko)
*
|
2010-01-27 |
2012-11-08 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
|
|
CN102740909B
(zh)
|
2010-02-01 |
2016-05-04 |
赛诺菲-安万特德国有限公司 |
药筒保持器、给药装置和用于将药筒固定在药筒保持器中的方法
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
CA2793737A1
(en)
|
2010-03-24 |
2011-09-29 |
Shifamed Holdings, Llc |
Intravascular tissue disruption
|
|
EP2552951A1
(en)
|
2010-03-26 |
2013-02-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
AR080592A1
(es)
*
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
|
MX2012013001A
(es)
|
2010-05-13 |
2013-02-26 |
Univ Indiana Res & Tech Corp |
Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
|
|
JP6050746B2
(ja)
|
2010-05-13 |
2016-12-21 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
EP2571900A1
(en)
|
2010-05-20 |
2013-03-27 |
Glaxo Group Limited |
Improved anti-serum albumin binding variants
|
|
WO2011156407A2
(en)
|
2010-06-09 |
2011-12-15 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonists to treat pancre-atitis
|
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
|
IL223742A
(en)
|
2010-06-21 |
2016-06-30 |
Mannkind Corp |
A dry powder inhaler and preparation for it
|
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
EP2588126A4
(en)
|
2010-06-24 |
2015-07-08 |
Univ Indiana Res & Tech Corp |
AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
|
|
WO2011162830A2
(en)
|
2010-06-24 |
2011-12-29 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
JP2013535471A
(ja)
|
2010-07-28 |
2013-09-12 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
安定化した領域を有するｇｌｐ−１受容体アゴニスト化合物
|
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
CA2812951A1
(en)
|
2010-09-28 |
2012-04-19 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides having enhanced duration of action
|
|
EP2635296B1
(en)
|
2010-11-03 |
2014-12-24 |
Arecor Limited |
Novel composition comprising glucagon
|
|
MX340112B
(es)
|
2010-11-09 |
2016-06-27 |
Mannkind Corp |
Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
|
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
|
CN102552883B
(zh)
|
2010-12-09 |
2014-02-19 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
|
SI2651398T1
(en)
|
2010-12-16 |
2018-04-30 |
Novo Nordisk A/S |
SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
|
|
US8507428B2
(en)
|
2010-12-22 |
2013-08-13 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting GIP receptor activity
|
|
US9161953B2
(en)
|
2010-12-22 |
2015-10-20 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonists for islet cell transplantation
|
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
|
AU2012225268B2
(en)
|
2011-03-10 |
2016-10-20 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of peptide drugs
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
CN106928341B
(zh)
|
2011-03-30 |
2021-06-01 |
上海仁会生物制药股份有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
|
DK2694095T3
(en)
|
2011-04-05 |
2018-05-28 |
Longevity Biotech Inc |
COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
|
|
EP2696897A2
(en)
|
2011-04-11 |
2014-02-19 |
Yeda Research and Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
|
DK2710031T3
(en)
|
2011-05-18 |
2018-01-02 |
Mederis Diabetes Llc |
IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
|
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
UA126465C2
(uk)
|
2011-06-10 |
2022-10-12 |
Ханмі Сайенс Ко., Лтд. |
Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
|
|
US9453062B2
(en)
|
2011-06-10 |
2016-09-27 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
|
|
NZ618331A
(en)
|
2011-06-17 |
2016-04-29 |
Halozyme Inc |
Stable formulations of a hyaluronan-degrading enzyme
|
|
RU2607365C2
(ru)
|
2011-06-17 |
2017-01-10 |
Ханми Сайенс Ко., Лтд. |
Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
|
|
KR20140043793A
(ko)
|
2011-06-22 |
2014-04-10 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-작용물질
|
|
RS56173B1
(sr)
|
2011-06-22 |
2017-11-30 |
Univ Indiana Res & Tech Corp |
Koagonisti receptora za glukagon/glp-1 receptora
|
|
WO2012177929A2
(en)
|
2011-06-24 |
2012-12-27 |
Amylin Pharmaceuticals, Inc. |
Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
|
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
DK2741765T3
(en)
|
2011-08-10 |
2016-06-13 |
Adocia |
Injectable solution of at least one type of basal insulin
|
|
CN104023784B
(zh)
|
2011-08-24 |
2018-05-25 |
费斯生物制药公司 |
供持续释放的活性剂制剂
|
|
CN103189389B
(zh)
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
|
AU2012311484B2
(en)
|
2011-09-23 |
2017-04-13 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
MX359329B
(es)
|
2011-10-28 |
2018-09-25 |
Sanofi Aventis Deutschland |
Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.
|
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
|
JP6324315B2
(ja)
|
2011-11-17 |
2018-05-16 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
|
|
SG11201401597TA
(en)
|
2011-11-29 |
2014-05-29 |
Jurox Pty Ltd |
Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
BR112014014898A2
(pt)
|
2011-12-22 |
2020-10-27 |
Pfizer Inc. |
processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2
|
|
IN2014CN04401A
(enExample)
|
2011-12-23 |
2015-09-04 |
Zealand Pharma As |
|
|
EP2797585A4
(en)
|
2011-12-29 |
2015-10-07 |
Latitude Pharmaceuticals Inc |
STABILIZED GLUCAGONNANOULULSIONS
|
|
US9198971B2
(en)
|
2012-01-09 |
2015-12-01 |
Adocia |
Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
|
|
HK1208155A1
(en)
|
2012-03-28 |
2016-02-26 |
Amylin Pharmaceuticals, Llc |
Transmucosal delivery of engineered polypeptides
|
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
CN102649947A
(zh)
|
2012-04-20 |
2012-08-29 |
无锡和邦生物科技有限公司 |
一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
|
|
US20150111246A1
(en)
|
2012-04-24 |
2015-04-23 |
Astrazeneca Pharmaceuticals Lp |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
IN2014MN02304A
(enExample)
|
2012-05-03 |
2015-08-07 |
Zealand Pharma As |
|
|
CN104540850B
(zh)
|
2012-05-03 |
2018-05-18 |
西兰制药公司 |
胰高血糖素样肽2(glp-2)类似物
|
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
|
CN103421094A
(zh)
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
|
WO2013177565A1
(en)
|
2012-05-25 |
2013-11-28 |
Amylin Pharmaceuticals, Llc |
Insulin-pramlintide compositions and methods for making and using them
|
|
SG11201407860PA
(en)
|
2012-06-14 |
2014-12-30 |
Sanofi Sa |
Exendin-4 peptide analogues
|
|
CN104583232B
(zh)
|
2012-06-21 |
2018-04-13 |
印第安纳大学研究及科技有限公司 |
展现gip受体活性的胰高血糖素类似物
|
|
PE20150863A1
(es)
|
2012-06-21 |
2015-06-11 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que exhiben actividad de receptor de gip
|
|
CN104619369B
(zh)
|
2012-07-12 |
2018-01-30 |
曼金德公司 |
干粉药物输送系统和方法
|
|
IN2015DN00544A
(enExample)
|
2012-07-23 |
2015-06-26 |
Zealand Pharma As |
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
EP2934562A1
(en)
|
2012-08-14 |
2015-10-28 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
EP2931300A1
(en)
|
2012-08-14 |
2015-10-21 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
|
WO2014041375A1
(en)
|
2012-09-17 |
2014-03-20 |
Imperial Innovations Limited |
Peptide analogues of glucagon and glp1
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
WO2014073842A1
(en)
|
2012-11-06 |
2014-05-15 |
Hanmi Pharm. Co., Ltd. |
Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
|
|
MX360816B
(es)
|
2012-11-20 |
2018-11-15 |
Mederis Diabetes Llc |
Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
|
|
TWI617574B
(zh)
|
2012-12-11 |
2018-03-11 |
梅迪繆思有限公司 |
用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
|
|
AU2013366692B2
(en)
*
|
2012-12-21 |
2017-11-23 |
Sanofi |
Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
|
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
|
CA2902352A1
(en)
|
2013-03-14 |
2014-09-18 |
Medimmune Limited |
Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
|
|
JP6538645B2
(ja)
|
2013-03-14 |
2019-07-03 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
インスリン‐インクレチン複合物
|
|
JP2016521253A
(ja)
|
2013-03-15 |
2016-07-21 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
持続性作用を有するプロドラッグ
|
|
EP2986313B1
(en)
|
2013-04-18 |
2019-06-12 |
Novo Nordisk A/S |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
PL3057984T3
(pl)
|
2013-10-17 |
2018-12-31 |
Zealand Pharma A/S |
Acylowane analogi glukagonu
|
|
CN105829339B
(zh)
|
2013-11-06 |
2021-03-12 |
西兰制药公司 |
胰高血糖素-glp-1-gip三重激动剂化合物
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
TW201609798A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
Ｅｘｅｎｄｉｎ－４胜肽類似物
|
|
TW201609800A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
|
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
|
MX2016008978A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
|
|
MX2016008979A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
|
|
GB201404002D0
(en)
|
2014-03-06 |
2014-04-23 |
Imp Innovations Ltd |
Novel compounds
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN104926934B
(zh)
|
2014-09-23 |
2016-11-09 |
蒋先兴 |
胃泌酸调节素类似物
|
|
CN107108713A
(zh)
|
2014-10-10 |
2017-08-29 |
诺和诺德股份有限公司 |
稳定的基于glp‑1的glp‑1/胰高血糖素受体共激动剂
|
|
CN107108715A
(zh)
|
2014-10-24 |
2017-08-29 |
默沙东公司 |
胰高血糖素和glp‑1受体的共激动剂
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|
|
WO2016198604A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|